Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Orlistat on Liver Fat Content in Obese Subjects with NAFLD and High Plasma Proneurotensin
2022-500366-10-00Phase 2Completed
- Sponsor
- Region Skåne
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of orlistat in metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity (2 arms), sponsored by Region Skåne. Started Jan 2024; status: completed.
02
Drugs
orlistat
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)obesity
Beyond the preview
Go deeper on 2022-500366-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500366-10-00.